eLife (Jul 2022)

Response to immune checkpoint blockade improved in pre-clinical model of breast cancer after bariatric surgery

  • Laura M Sipe,
  • Mehdi Chaib,
  • Emily B Korba,
  • Heejoon Jo,
  • Mary Camille Lovely,
  • Brittany R Counts,
  • Ubaid Tanveer,
  • Jeremiah R Holt,
  • Jared C Clements,
  • Neena A John,
  • Deidre Daria,
  • Tony N Marion,
  • Margaret S Bohm,
  • Radhika Sekhri,
  • Ajeeth K Pingili,
  • Bin Teng,
  • James A Carson,
  • D Neil Hayes,
  • Matthew J Davis,
  • Katherine L Cook,
  • Joseph F Pierre,
  • Liza Makowski

DOI
https://doi.org/10.7554/eLife.79143
Journal volume & issue
Vol. 11

Abstract

Read online

Bariatric surgery is a sustainable weight loss approach, including vertical sleeve gastrectomy (VSG). Obesity exacerbates tumor growth, while diet-induced weight loss impairs progression. It remains unknown how bariatric surgery-induced weight loss impacts cancer progression or alters response to therapy. Using a pre-clinical model of obesity followed by VSG or diet-induced weight loss, breast cancer progression and immune checkpoint blockade therapy were investigated. Weight loss by VSG or weight-matched dietary intervention before tumor engraftment protected against obesity-exacerbated tumor progression. However, VSG was not as effective as diet in reducing tumor burden despite achieving similar weight and adiposity loss. Leptin did not associate with changes in tumor burden; however, circulating IL-6 was elevated in VSG mice. Uniquely, VSG tumors displayed elevated inflammation and immune checkpoint ligand PD-L1+ myeloid and non-immune cells. VSG tumors also had reduced T lymphocytes and markers of cytolysis, suggesting an ineffective anti-tumor microenvironment which prompted investigation of immune checkpoint blockade. While obese mice were resistant to immune checkpoint blockade, anti-PD-L1 potently impaired tumor progression after VSG through improved anti-tumor immunity. Thus, in formerly obese mice, surgical weight loss followed by immunotherapy reduced breast cancer burden. Finally, we compared transcriptomic changes in adipose tissue after bariatric surgery from patients and mouse models. A conserved bariatric surgery-associated weight loss signature (BSAS) was identified which significantly associated with decreased tumor volume. Findings demonstrate conserved impacts of obesity and bariatric surgery-induced weight loss pathways associated with breast cancer progression.

Keywords